a small-molecule oral agonist of the human glucagon-like peptide-1 receptor Glucagon - Thepharmacological basis for nonpeptide agonismof theGLP-1receptorby orforglipron agonists Revolutionizing Diabetes and Obesity Treatment: The Rise of the Small-Molecule Oral GLP-1 Receptor Agonist

Emerging glp1 receptoragonists The landscape of metabolic disease management is undergoing a significant transformation, largely driven by the advent of small-molecule oral agonists of the human glucagon-like peptide-1 receptor. For years, peptide agonists of the glucagon-like peptide-1 receptor (GLP-1R), such as injectable semaglutide, have revolutionized diabetes therapy and shown promise in obesity treatment.A comprehensive review of currently disclosedsmall molecule GLP-1 receptorligands is presented and examples of “ligand bias” and “probe dependency” for ... However, their limitations, including the need for injection and sometimes dietary restrictions, have spurred a quest for more convenient and accessible alternatives. This has led to the development of a new class of therapeutics: oral small-molecule GLP-1 receptor agonists.

These novel compounds are designed to mimic the actions of endogenous incretins, stimulating insulin release and inhibiting glucagon secretion in a glucose-dependent manner. This mechanism is crucial for improving glycemic control in individuals with type 2 diabetes mellitus (T2DM). Furthermore, the satiety-inducing effects of GLP-1 agonists contribute to weight reduction, making them valuable agents for managing obesity.作者：DA Griffith·2022·被引用次数：178—(3) Activation of theGLP-1 receptor(GLP-1R) byGLP-1stimulates insulin release and inhibits glucagon secretion in a glucose-dependent manner.

A prominent example in this evolving field is danuglipron, previously identified as PF-06882961. This orally administered small molecule has demonstrated its ability to activate the GLP-1 receptor and effectively lower blood glucose levels in humans. Research efforts, including a randomized clinical trial investigating the efficacy, safety, and tolerability of danuglipron treatment for 16 weeks in adults with type 2 diabetes, highlight its therapeutic potential. Studies have shown that danuglipron is a potent agonist of the human glucagon-like peptide-1 receptor, contributing to reduced plasma glucose and body weight.

Another compelling candidate is orforglipron, a small-molecule, nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist that is currently being investigated. Clinical trials with daily oral orforglipron have associated its use with significant weight reduction, with reported adverse events being comparable to those seen with other GLP-1 receptor agonists. The pharmacological basis for the nonpeptide agonism of the GLP-1 receptor by orforglipron is a subject of ongoing research, aiming to understand its unique mechanisms.

Beyond these leading contenders, a growing pipeline of oral small-molecule GLP-1 receptor agonists is emerging. ECC5004, also known as AZD5004, is an orally bioavailable, nonpeptidic GLP-1 receptor agonist initially developed by Eccogene and subsequently advanced.Potential oral small-molecule GLP-1R agonist. | DDDT Similarly, PK2, described as an orally active nonpeptidic GLP1R agonist, has shown efficacy in preserving or restoring functional beta-cell mass.A Small-Molecule Oral Agonist of the Human Glucagon-like ... MLX-7005 is another highly potent, oral small-molecule GLP-1 receptor agonist that robustly activates the GLP-1 receptor cAMP signaling, demonstrating its therapeutic promise.

Further innovations include lotiglipron (PF-07081532), a once-daily, oral small-molecule glucagon-like peptide-1 receptor agonist, which is undergoing investigation作者：HJ Choe·2021·被引用次数：41—We focus on the pharmacokinetic and pharmacodynamic properties of the recently approved oral GLP-1 receptor agonist,oral semaglutide. Small molecule oral GLP-1 .... AZD0186 has also emerged as a potent agonist of the human glucagon-like peptide-1 receptor, showing improvements in glucose control and reductions in body weight in preclinical evaluations and early human trials.

The development of these small molecules represents a significant leap forward作者：S Wharton·2023·被引用次数：423—Daily oral orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with weight reduction. Adverse events reported with orforglipron were similar to .... Unlike peptide-based therapies, small molecule GLP-1 receptor agonists offer the potential for greater oral bioavailability and simpler administration作者：OC Șeremet·2025—In in vitro experiments,TTP-273demonstrated strong potency and high selectivity as a GLP-1R agonist, eliciting a concentration-dependent increase in receptor .... While oral semaglutide has already made waves, the emergence of entirely small molecule versions like danuglipron and orforglipron addresses limitations inherent in even orally administered peptides, such as potential requirements for diet restriction and specific timing of administration.

The field also explores different classes of agonists, including ago-allosteric modulators selective for the human GLP-1 receptor, which represent a unique approach to receptor activation. Researchers are also investigating compounds like cinchonine, a potential oral small-molecule GLP-1R agonist that may offer benefits beyond glucose control, potentially ameliorating conditions like non-alcoholic steatohepatitis (NASH). The development of YN1548, a selective small-molecule GLP-1 receptor agonist for T2DM and obesity, further underscores the breadth of innovation.作者：K Girdhar·2022·被引用次数：13—This report describes a small molecule,PK2, as an orally active nonpeptidic GLP1R agonist that has efficacy to preserve or restore functional β-cell mass.

The journey from initial discovery to widespread clinical application involves rigorous scientific inquiry. Publications detailing the design, synthesis, and biological evaluation of small molecules targeting the GLP-1 receptor are critical for advancing the field.A small-molecule oral agonist of the human glucagon-like ... Comprehensive reviews of disclosed small molecule GLP-1 receptor ligands and analysis of their properties, including ligand bias and probe dependency, are essential for understanding the nuances of receptor interaction. Promising compounds like TTP-273, a newer iteration of TT-OAD2, are undergoing clinical trials, with early results indicating strong efficacy for blood glucose control.Glucagon-like receptor agonists and next-generation ...

In conclusion, the development of a small-molecule oral agonist of the human glucagon-like peptide-1 receptor marks a pivotal moment in the treatment of metabolic disorders.Small-molecule agonists for the glucagon-like peptide 1 ... These innovative therapies promise improved patient convenience, enhanced efficacy, and broader accessibility, offering new hope for individuals managing type 2 diabetes and obesity作者：R ONO·2022·被引用次数：4—Danuglipron is anoral small molecule glucagon-like peptide-1 receptor(GLP-1R)agonistshown to reduce plasma glucose and body weight after .... The ongoing research and expanding pipeline of these small molecules suggest a future where managing these conditions is more manageable and effective than ever before.